MAP2K7 and neoplasm: Among them, IGF1R and EGFR can activate PI3K/AKT and MEK/ERK signaling pathways, respectively, to enhance tumor progression and drug resistance [184, 185], and YY1 activates Wnt/β-catenin signaling by promoting CTNNB1 expression to promote tumor growth [186].